Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(3 months from now) | |
US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(3 months from now) |
Market Authorisation Date: 28 April, 2009
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: SOLUTION;ORAL
5
United States
2
Korea, Republic of
2
European Union
1
China
1
Australia
1
Spain
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic